Laval, Québec, October 19, 2022 – Altasciences’ laboratory facilities in Columbia, MO, are undergoing a significant expansion, with completion expected in 2023. The new 8,000-square-foot space will mirror Altasciences’ current bioanalytical laboratory in Laval, Québec, with state-of-the-art equipment and bioanalytical capabilities. This will supplement the service offering already available at Altasciences’ site in Seattle, WA, to support preclinical and clinical studies conducted in the U.S. 

The laboratory’s strategic location, in close proximity to both preclinical and clinical facilities, reflects Altasciences’ focus on ensuring a seamless collaboration between teams, sites, and phases of development. 

“We are very excited about the laboratory expansion at our Columbia site. With this additional full-service, state-of-the-art bioanalytical and flow cytometry laboratory, we look forward to continuing to provide our usual high-quality, timely analyses of study samples for our clients,” said Lynne Le Sauteur, Vice President, Laboratory Sciences, at Altasciences.

Conveniently located in the Midwest, the Columbia site is near a fast-growing university town that is easily accessible from across the country. The bioanalytical laboratory will contain 48 workbenches in an open space, with services that include mass spectrometry and ligand binding assays, flow cytometry, biomarkers, as well as cell culture.

“At Altasciences, we continue to increase capacity in support of our strategic growth plan, and look forward to the completion of this new laboratory to supplement our existing North American service offering,” stated Andy Brown, Columbia Site Director, at Altasciences.

About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com  

Laval, Québec, October 14, 2022 – Altasciences hired two expert advisors to support its strategic growth in Europe, while its preclinical team continues to expand with the addition of two key employees.

Providing strategic input into steering Altasciences’ drug development solutions direction in Europe, Peter Varney joins the company as Pharma Development and Strategy Advisor. Peter brings 40 years of experience in commercial development, strategic alliances, and relationship management at Covance/Labcorp to his new position. Hazel Clay, with over 30 years of experience in supporting the development of innovator pharmaceutical assets at Covance/Labcorp, plays a key role as Drug Development Advisor in Altasciences’ European expansion. Both Peter and Hazel are based out of Altasciences’ offices in Harrogate, UK.

"With their extensive experience and keen strategic vision, Peter and Hazel are important assets to Altasciences’ expansion into the European market. We wanted to provide our European clients access to in-depth knowledge on early phase drug development to help them get better drugs to market faster," stated Chris Perkin, Altasciences’ Chief Executive Officer.

In addition, Dr. Lisa Biegel joins Altasciences as Senior Scientific Director, Preclinical Services, and will be based at the Columbia, MO, facility. With over 30 years of industry experience in regulatory toxicology at Covance/Labcorp, Lisa will provide leadership and oversight, as well as strategic scientific input, to the study direction and reporting teams.

Furthermore, Annette Kenser joins Altasciences as Senior Director of Quality Assurance, Preclinical Research. Annette has extensive experience as a scientific quality assurance auditor, and will focus on identifying areas of improvement while aligning quality assurance activities throughout the organization.

"We are pleased to welcome Lisa and Annette to Altasciences, and look forward to benefitting from their talents and contributions in the preclinical space," said Andy Brown, Site Director at Altasciences’ Columbia preclinical facility.

About Altasciences
Altasciences is an integrated drug development solution company offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.

Julie-Ann Cabana
Altasciences
+1 514 601-9763
jcabana@altasciences.com

• Read more about Immunogenicity Target Interference: A Novel Blocking Approach